Premium
Synthesis, Biological Evaluation and In Silico Studies of 1,2,4‐Triazole and 1,3,4‐Thiadiazole Derivatives as Antiherpetic Agents
Author(s) -
Goma'a HebatAllah M.,
Ghaly Mariam A.,
Abouzeid Laila A.,
Badria Farid A.,
Shehata Ihsan A.,
ElKerdawy Mohamed M.
Publication year - 2019
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.201900814
Subject(s) - in silico , chemistry , herpes simplex virus , docking (animal) , triazole , combinatorial chemistry , selectivity , virtual screening , lead compound , active compound , stereochemistry , drug , biological activity , active site , thymidine kinase , molecular model , pharmacology , drug discovery , virus , enzyme , biochemistry , in vitro , virology , biology , organic chemistry , medicine , gene , nursing , catalysis
Two isosteric series of 1,2,4‐triazole and 1,3,4‐thiadiazole derivatives were designed and synthesized in this work to be evaluated for their antiviral activity. Compounds 2–9 and 11–19 were synthesized and their antiviral activity was tested against herpes simplex virus type 1, HSV‐1, using acyclovir, ACV, as a reference drug. In addition, molecular docking into the active site of HSV‐1 thymidine kinase was performed to interpret the data obtained from biological testing, and all compounds were subjected to an in silico screening of their physicochemical properties to estimate their drug‐likeness and safety. The results revealed that compound 7 was able to reduce the viral plaques by 50% at a dose of 80 μM, but interestingly, retained high selectivity compared to ACV (>200 μM vs. 80 μM). The best effective and safe compound in this study, 7 , was further tested for its combined effects with ACV on the anti‐HSV‐1 activity in the plaque reduction assay. Compound 7 proved to improve the selectivity of ACV and reduce its effective dose that produced 100% inhibition of viral plaques. The triazolopyrimidine 7 is suggested to be a promising candidate for further development as an antiherpetic agent. Molecular docking into the active site of HSV‐1 thymidine kinase emphasized the superior interaction of compound 7 .